News | Hemodynamic Support Devices | November 02, 2015

Miracor’s PiCSO Impulse System Highlighted at TCT 2015

Device may offer improved heart attack outcomes as novel therapy for cardioprotected PCI in the future

Miracor, PiCSO Impulse System, TCT 2015, cardioprotection during PCI, acute myocardial infarction

November 2, 2015 — Miracor Medical Systems GmbH announced that its PiCSO system was highlighted during the 2015 Transcatheter Cardiovascular Therapeutics (TCT) conference in San as offering new hope for cardioprotection during percutaneous coronary intervention (PCI).

Myocardial salvage and the need for cardioprotection for patients with acute myocardial infarction (AMI) was a focus topic at the conference.

“Despite recent improvements in the treatment of AMI, including shortened door-to-balloon times and advanced pharmacological strategies, survival has plateaued, and novel strategies are needed to reduce infarct size and improve clinical outcomes, especially in patients with large ST-segment elevation MI (STEMI),” stated Gregg W. Stone, M.D., professor of medicine at Columbia University College and director of cardiovascular research and education at the New York-Presbyterian Hospital Center for Interventional Vascular Therapies, during a symposium on novel strategies in PCI with focus on PiCSO Therapy. “In recent years, many approaches to improve reperfusion success and myocardial salvage have failed. Emerging data suggests that the effective delivery of PICSO improves myocardial perfusion and may reduce infarct size in STEMI patients,” he continued.

PiCSO is applied during the stenting procedure, directly following flow restoration, and increases myocardial perfusion and microcirculation, thereby preventing so-called reperfusion injury — damage to the myocardium caused by the stenting procedure itself.

“Further therapies to protect my patients — especially during complex PCI procedures — are needed. At San Raffaele Hospital, we have used PiCSO in elective, as well as acute, high-risk PCI procedures and are pleased to see that PiCSO can be applied without significant interruption of our standard workflows and without increasing the risk for the patient,” said Antonio Colombo, M.D., director of cardiovascular interventions at San Raffaele Scientific Institute, Columbus Hospital in Milan, Italy. “Once the PiCSO catheter is placed in the coronary sinus and connected to the PiCSO console, therapy is applied fully automatically so that I can focus on the stenting procedure, knowing that the patient’s heart is protected by PiCSO.”

For more information: www.miracormedical.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init